Aid in decision making for the choice of therapy for patients with breast cancer: Prognostic and predictive factors;Entscheidungshilfen bei der therapiewahl für patientinnen mit mammakarzinom: Prognose- und prädiktivfaktoren

Gynakologe

Volumn 38, Issue 5, 2005, Pages 388-397

  Fasching, P A ^a   Lux, M P ^a   Beckmann, K ^a   Strick, R ^a   Beckmann, M W ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Breast cancer; Molecular medicine; Predictive factor; Prognostic factor; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PARAFFIN; PLASMINOGEN ACTIVATOR; TAMOXIFEN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER THERAPY; COMPUTER MODEL; COMPUTER PROGRAM; FROZEN SECTION; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DECISION MAKING; PREDICTION; PROGNOSIS; PUBLICATION; RISK ASSESSMENT; TREATMENT PLANNING; TUMOR VOLUME;

EID: 21244450011     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00129-005-1680-6     Document Type: Article

References (32)

1. Fisher B, Gebhardt MC (1978) The evolution of breast cancer surgery: past, present, and future. Semin Oncol 5: 385-394
2. EBCTCG (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467
3. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822
4. EBCTCG (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942
5. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS (1983) Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 309: 1343-1347
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
7. Harbeck N, Kates RE, Look MP et al. (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62: 4617-4622
8. Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6: 375-392
9. Fisher B, Bryant J, Wolmark N et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
10. Kuerer HM, Newman LA, Smith TL et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
11. Bear HD, Anderson S, Smith RE et al. (2004) A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 88 [Suppl 1]: S16
12. Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983
13. Beckmann MW, Fasching PA, Weiss JM, Magener A, Ortmann O (2003) Update primäres Mammakarzinom 2003. Geburtshilfe Frauenheilkd 04: R66-R91
14. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181-187
15. Julian TB, Krag D, Brown A et al. (2004) Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 88 [Suppl 1]: S11
16. Verbanac KM, Min J, Mannie AE, Tafra L (2004) Clinical significance of PCR-detected metastases in sentinel nodes of breast cancer patients: An interim report. J Clin Oncol 22: 14S
17. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076-1087
18. Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, Rauschecker H (1993) The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 25: 235-245
19. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95: 681-695
20. Loehberg CR, Lux M, Ackermann S et al. (2005) Neoadjuvant Chemotherapy in Breast Cancer: Which Diagnostics can be used? Anticancer Res (accepted)
21. Berry DA, Cirrincione C, Henderson IC et al. (2004) Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor, node positive breast cancer: 20-year experience of the CALGB & U.S.Breast Intergroup. Breast Cancer Res Treat 88 [Suppl 1]: S17
22. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944-948
23. Allred DC, Clark GM, Tandon AK et al. (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605
24. Gusterson BA, Gelber RD, Goldhirsch A et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056
25. Look MP, van Putten WL, Duffy MJ et al. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128
26. Ayers M, Symmans WF, Stec J et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293
27. Paik S, Shak S, Tang G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826
28. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991
29. Ravdin PM, Davis GJ (2004) A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen. Clin Breast Cancer 5: 313-316
30. Harbeck N, Thomssen C (2003) u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast. Zentralbl Gynakol 125: 362-367
31. Osborne K (2005) Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 14 [Suppl 1]: S5
32. Dowsett M (2003) Analysis of time to recurrence in the ATAC trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82 [Suppl 1]: S7